ME01959B - Upotreba agomelatina za dobijanje lekova namenjenih lečenju smith-magenis sindroma - Google Patents
Upotreba agomelatina za dobijanje lekova namenjenih lečenju smith-magenis sindromaInfo
- Publication number
- ME01959B ME01959B MEP-2011-219A MEP21911A ME01959B ME 01959 B ME01959 B ME 01959B ME P21911 A MEP21911 A ME P21911A ME 01959 B ME01959 B ME 01959B
- Authority
- ME
- Montenegro
- Prior art keywords
- agomelatine
- magenis syndrome
- obtain medication
- smith
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Primary Cells (AREA)
- Connection Of Batteries Or Terminals (AREA)
- General Preparation And Processing Of Foods (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0610296A FR2908995B1 (fr) | 2006-11-24 | 2006-11-24 | Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement du syndrome de smith magenis |
EP07291391A EP1929999B1 (fr) | 2006-11-24 | 2007-11-23 | Utilisation de l'agomélatine pour l'obtention de médicaments destines au traitement du syndrome de smith magenis |
Publications (1)
Publication Number | Publication Date |
---|---|
ME01959B true ME01959B (me) | 2011-10-31 |
Family
ID=38229648
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MEP-2011-219A ME01959B (me) | 2006-11-24 | 2007-11-23 | Upotreba agomelatina za dobijanje lekova namenjenih lečenju smith-magenis sindroma |
Country Status (38)
Country | Link |
---|---|
US (1) | US20080132577A1 (me) |
EP (1) | EP1929999B1 (me) |
JP (1) | JP2008127395A (me) |
KR (2) | KR20080047299A (me) |
CN (1) | CN101194901A (me) |
AR (1) | AR063896A1 (me) |
AT (1) | ATE501717T1 (me) |
AU (1) | AU2007234614B2 (me) |
BR (1) | BRPI0704453A2 (me) |
CA (1) | CA2610638C (me) |
CL (1) | CL2007003396A1 (me) |
CY (1) | CY1111430T1 (me) |
DE (1) | DE602007013166D1 (me) |
DK (1) | DK1929999T3 (me) |
EA (1) | EA013471B1 (me) |
ES (1) | ES2363252T3 (me) |
FR (1) | FR2908995B1 (me) |
GE (1) | GEP20094746B (me) |
HR (1) | HRP20110370T1 (me) |
JO (1) | JO2656B1 (me) |
MA (1) | MA29523B1 (me) |
ME (1) | ME01959B (me) |
MX (1) | MX2007014199A (me) |
MY (1) | MY145139A (me) |
NO (1) | NO338951B1 (me) |
NZ (1) | NZ563684A (me) |
PE (1) | PE20081347A1 (me) |
PL (1) | PL1929999T3 (me) |
PT (1) | PT1929999E (me) |
RS (1) | RS51676B (me) |
SA (1) | SA07280635B1 (me) |
SG (1) | SG143203A1 (me) |
SI (1) | SI1929999T1 (me) |
TW (1) | TWI370735B (me) |
UA (1) | UA94042C2 (me) |
UY (1) | UY30704A1 (me) |
WO (1) | WO2008071870A2 (me) |
ZA (1) | ZA200710103B (me) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PH12012000132A1 (en) * | 2011-06-09 | 2014-10-20 | Servier Lab | New co-crystals of agomelatine, a process for their preparation and pharmaceutical compositions containing them |
FR2978916B1 (fr) * | 2011-08-10 | 2013-07-26 | Servier Lab | Composition pharmaceutique solide pour administration buccale d'agomelatine |
HUE036989T2 (hu) | 2013-06-06 | 2018-08-28 | Zentiva Ks | Agomelatin készítmény, amely agomelatint ko-kristály formájában tartalmaz |
EP2810647A1 (en) * | 2013-06-06 | 2014-12-10 | Zentiva, a.s. | Pharmaceutical formulations comprising agomelatine in the form of agomelatine co-crystal with an organic acid |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1564202A (en) * | 1924-05-20 | 1925-12-08 | Christensen Jens Herman | Method of producing water-insoluble multicolored screens |
FR2658818B1 (fr) | 1990-02-27 | 1993-12-31 | Adir Cie | Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
FR2866335B1 (fr) * | 2004-02-13 | 2006-05-26 | Servier Lab | Nouveau procede de synthese de l'agomelatine |
-
2006
- 2006-11-24 FR FR0610296A patent/FR2908995B1/fr not_active Expired - Fee Related
-
2007
- 2007-01-01 ZA ZA200710103A patent/ZA200710103B/en unknown
- 2007-11-07 PE PE2007001528A patent/PE20081347A1/es not_active Application Discontinuation
- 2007-11-08 UY UY30704A patent/UY30704A1/es not_active Application Discontinuation
- 2007-11-13 MX MX2007014199A patent/MX2007014199A/es active IP Right Grant
- 2007-11-13 MY MYPI20071976A patent/MY145139A/en unknown
- 2007-11-19 MA MA30379A patent/MA29523B1/fr unknown
- 2007-11-21 US US11/986,501 patent/US20080132577A1/en not_active Abandoned
- 2007-11-22 AU AU2007234614A patent/AU2007234614B2/en not_active Ceased
- 2007-11-22 CL CL200703396A patent/CL2007003396A1/es unknown
- 2007-11-22 JO JO2007487A patent/JO2656B1/en active
- 2007-11-22 JP JP2007302457A patent/JP2008127395A/ja active Pending
- 2007-11-22 GE GEAP200710391A patent/GEP20094746B/en unknown
- 2007-11-22 AR ARP070105184A patent/AR063896A1/es unknown
- 2007-11-23 DK DK07291391.6T patent/DK1929999T3/da active
- 2007-11-23 UA UAA200713021A patent/UA94042C2/ru unknown
- 2007-11-23 AT AT07291391T patent/ATE501717T1/de active
- 2007-11-23 PL PL07291391T patent/PL1929999T3/pl unknown
- 2007-11-23 ME MEP-2011-219A patent/ME01959B/me unknown
- 2007-11-23 EA EA200702318A patent/EA013471B1/ru not_active IP Right Cessation
- 2007-11-23 SG SG200718042-5A patent/SG143203A1/en unknown
- 2007-11-23 RS RS20110157A patent/RS51676B/en unknown
- 2007-11-23 NZ NZ563684A patent/NZ563684A/en not_active IP Right Cessation
- 2007-11-23 CN CNA2007103061420A patent/CN101194901A/zh active Pending
- 2007-11-23 DE DE602007013166T patent/DE602007013166D1/de active Active
- 2007-11-23 SI SI200730595T patent/SI1929999T1/sl unknown
- 2007-11-23 CA CA2610638A patent/CA2610638C/fr not_active Expired - Fee Related
- 2007-11-23 PT PT07291391T patent/PT1929999E/pt unknown
- 2007-11-23 BR BRPI0704453-4A patent/BRPI0704453A2/pt not_active Application Discontinuation
- 2007-11-23 KR KR1020070120251A patent/KR20080047299A/ko not_active Application Discontinuation
- 2007-11-23 ES ES07291391T patent/ES2363252T3/es active Active
- 2007-11-23 TW TW096144583A patent/TWI370735B/zh not_active IP Right Cessation
- 2007-11-23 NO NO20075989A patent/NO338951B1/no not_active IP Right Cessation
- 2007-11-23 WO PCT/FR2007/001926 patent/WO2008071870A2/fr active Application Filing
- 2007-11-23 EP EP07291391A patent/EP1929999B1/fr active Active
- 2007-11-24 SA SA07280635A patent/SA07280635B1/ar unknown
-
2011
- 2011-04-27 CY CY20111100416T patent/CY1111430T1/el unknown
- 2011-05-18 HR HR20110370T patent/HRP20110370T1/hr unknown
- 2011-07-06 KR KR1020110066825A patent/KR20110086673A/ko not_active Application Discontinuation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1127553A1 (en) | Use of pegylated il-10 to treat cancer | |
BRPI1007877A2 (pt) | "inibidores de dpp-iv para o tratamento de diabetes em pacientes pediátricos" | |
BR112012004166A8 (pt) | colocação otimizada de cânula para aplicação de agentes terapêuticos ao cérebro | |
ZA201007114B (en) | Compositions useful for the treatment of diabetes and other chronic disorder | |
ZA200808409B (en) | Use of rasagiline for the treatment of restless legs syndrome | |
BR112014005091A2 (pt) | composição farmacêutica para o tratamento do câncer compreendendo conjugado de interferon alfa | |
EP2182952A4 (en) | TREATMENT OF POST-TRAUMATIC STRESS DISORDER | |
ME01865B (me) | Upotreba agomelatina za dobijanje ljekova namijenjenih za tretman generalizovanog anksioznog poremećaja | |
IL215835A (en) | Carboxamide compounds and their use as a drug | |
HK1125831A1 (en) | Fat accumulation inhibitor for the treatment of metabolic syndrome | |
HK1232162A1 (zh) | 治療疼痛症狀及其它失調的化合物 | |
IL200013A0 (en) | Indenoisoquinolinone analogs and methods of use thereof | |
LTPA2016019I1 (lt) | Išsėtinės sklerozės (MS) gydymas kampatu-1H | |
SI1929999T1 (sl) | Uporaba agomelatina za izdelavo zdravila za zdravljenje sindroma Smith-Magenis | |
ZA201100165B (en) | Use of hdac inhibitors for the treatment of hodgkin's disease | |
IL211076A0 (en) | Novel methylenedioxy phenolic compounds and their use to treat disease | |
BRPI0914139A2 (pt) | composições pediátricas para o tratamento de esclerose múltipla | |
BRPI0722185A2 (pt) | Composições farmacêuticas para tratar ansiedade | |
EP2124950A4 (en) | PAIN TREATMENT WITH NALOXONE | |
SI1927351T1 (sl) | Uporaba agomelatina za pripravo zdravila za uporabo pri zdravljenju periventrikularne levkomalacije | |
BR112013007039A2 (pt) | "composição de tratamento pessoal" | |
IT1403064B1 (it) | Composizione di sostanze per il trattamento di pazienti con ipercolesterolemia e patologie collegate | |
EP2257303A4 (en) | USES OF MODIFIED ELR-CXC G31P CHEMOKINE | |
EP2219648A4 (en) | TREATMENT OF POSTRAUMATIC STRESS WITH TETRAHYDROINDOLONE ARYLPIPERAZINE COMPOUNDS | |
EP2356986A4 (en) | COMPOSITION FOR METABOLIC SYNDROME TREATMENT |